Publications by authors named "Ibtisam AlHarbi"
Background: The Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV) administration. However, the financial implications of this formulation have not been examined from the perspective of Saudi payers.
Methods And Materials: A prevalence-based budget impact model was developed to evaluate the financial effects of introducing "environment without" versus "with infliximab SC.
Article Synopsis
- - This study analyzes the budget impact of adopting three diabetes medications (semaglutide, tirzepatide, and dulaglutide) in Saudi Arabia, aiming to inform healthcare decision-makers about the financial implications for managing type 2 diabetes.
- - Using a prevalence-based model over five years, the total budget impacts were found to be approximately $85.9 million for semaglutide, $169.8 million for tirzepatide, and $94.6 million for dulaglutide, while factors such as cardiovascular complications and weight loss were analyzed to assess cost-effectiveness.
- - The findings indicate that semaglutide may be the most resource-efficient option for the Saudi healthcare budget due to lower
Article Synopsis
- Psoriasis is a chronic inflammatory condition that affects the skin and joints, with treatment focused on managing symptoms rather than curing the disease; biologic treatments like Risankizumab and Adalimumab target specific inflammatory pathways but have high costs.
- A retrospective study in Saudi Arabia compared the effectiveness and direct medical costs of Risankizumab versus Adalimumab for treating chronic plaque psoriasis, utilizing the Psoriasis Area and Severity Index and body surface area measures to assess outcomes.
- Results showed Risankizumab provided a greater reduction in severity scores compared to Adalimumab, but the differences were not statistically significant; additionally, Risankizumab had a higher annual treatment cost, highlighting the need for economic evaluations in treatment decisions